2Hales B F. Thalidomide on the comeback trail[J]. Nat Med, 1999, 5(5): 489.
3D'Amato R J, Loughnan M S, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082.
4Minor D R, Monroe D, Damico L A, et al. A phase Ⅱ study of thalidomide in advanced metastatic renal cell carcinoma[J]. Invest New Drugs, 2002, 20(4): 389.
5Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma[J]. Ann Oncol, 2002, 13(7): 1029.
6Desai A A, Vogelzang N J, Rini B I, et al. A high rate of venous thromboembolism in a multi-institutional phase Ⅱ trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma[J]. Cancer, 2002, 95(8): 1629.
7Hernberg M, Virkkunen P, Bono P, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma[J]. J Clin Oncol, 2003, 21(20): 3770.
8Amato R J. Thalidomide therapy for renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2003, 46 Suppl: S59.
9Motzer R J, Berg W, Ginsberg M, et al. Phase Ⅱ trial of thalidomide for patients with advanced renal cell carcinoma[J]. J Clin Oncol, 2002, 20(1): 302.
10Ng S S, Gutschow M, Weiss M, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues[J]. Cancer Res, 2003, 63(12): 3189.
